Pharmaceuticals Spain

Spain RSV Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Spain RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Spain · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $79.7 Mn Placeholder estimate
Estimate 2025 $88.5 Mn 2% of the global market
Projected 2034 $228.2 Mn 157.9% Adds $139.7 Mn over 9 forecast years
CAGR 2025–2034 11.1% Faster than 67% of 180 Pharmaceuticals markets here
Key players 5
  • Spain is 2.02% of the global market.
  • In Europe, the largest is Germany at $156.7 Mn.
  • Fastest growing: Russia at 12.3% a year.
  • Spain ranks 5th of 6 by size in Europe.

Market size projection

Spain

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$139.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
RSV Vaccines Market market size by year, Spain
YearMarket sizeChange that yearSince 2025
2024 (estimate) $79.7 Mn — —
2025 (base) $88.5 Mn +$8.8 Mn —
2026 (forecast) $98.3 Mn +$9.8 Mn +11.1%
2027 (forecast) $109.2 Mn +$10.9 Mn +23.4%
2028 (forecast) $121.4 Mn +$12.1 Mn +37.1%
2029 (forecast) $134.8 Mn +$13.5 Mn +52.4%
2030 (forecast) $149.8 Mn +$15.0 Mn +69.3%
2031 (forecast) $166.4 Mn +$16.6 Mn +88.1%
2032 (forecast) $184.9 Mn +$18.5 Mn +108.9%
2033 (forecast) $205.4 Mn +$20.5 Mn +132.1%
2034 (forecast) $228.2 Mn +$22.8 Mn +157.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.39 Bn
  2. North America $1.91 Bn
  3. US $1.67 Bn
  4. APAC $952.6 Mn
  5. Europe $754.4 Mn
  6. Canada $321.6 Mn
  7. China $306.6 Mn
  8. Japan $246.0 Mn
  9. Middle East $189.0 Mn
  10. Latin America $177.4 Mn
  11. Germany $156.7 Mn
  12. France $122.5 Mn
  13. Brazil $120.7 Mn
  14. UK $112.1 Mn
  15. Italy $114.1 Mn
  16. Spain (this report) $88.5 Mn
  17. India $85.4 Mn
  18. Ecuador $81.9 Mn
  19. Africa $75.1 Mn
  20. Saudi Arabia $73.0 Mn
  21. Mexico $66.4 Mn
  22. New Zealand $49.1 Mn
  23. Australia $47.9 Mn
  24. Russia $41.9 Mn
  25. South Africa $27.5 Mn
  26. UAE $25.3 Mn
  27. Egypt $12.2 Mn
  28. Philippines $10.1 Mn
  29. Hong Kong $7.6 Mn
  30. Malaysia $6.0 Mn
  31. Singapore $5.3 Mn
  32. Thailand $4.7 Mn
  33. Kenya $3.1 Mn

Report snapshot

Spain RSV Vaccines Market Analysis at a glance
Market size, 2025$88.5 Mn placeholder estimate
Forecast, 2034$228.2 Mn placeholder estimate
Growth (CAGR), 2025–203411.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersGSK PLC, Pfizer Inc., Moderna, Sanofi, AstraZeneca (see all)
Regulator in SpainAEMPSSource: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
Active clinical trials4 in SpainSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Spain RSV Vaccines Market Analysis Executive Summary

RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.

Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).

Bar chart: Spain RSV Vaccines market size, 2024–2034, placeholder estimates. $79.7 Mn in 2024, $88.5 Mn in 2025 and $228.2 Mn in 2034, 11.1% CAGR.
Spain RSV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Spain RSV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.

Competitive Landscape for RSV Vaccines Market in Spain

The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in Spain

RSV Vaccines in Spain: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.⁠[1] The National Health System (SNS), run by the regions, gives universal public care.⁠[2] ClinicalTrials.gov lists 4 studies on RSV Vaccines that are recruiting, active or about to start in Spain.⁠[3]

[1] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[2] Spanish Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RSV Vaccines right now, from free public sources.

Clinical trials

4 active trials in Spain

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. GSK PLC 6 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sanofi 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Guangzhou Patronus Biotech Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  5. MAXVAX Biotechnology Limited Liability Company 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 397 papers since 2021 (worldwide)

  1. The "ever-vaccinated" stock-flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy. Human vaccines & immunotherapeutics, 2026
  2. Decision-Making About Respiratory Syncytial Virus Immunization for Infants: Qualitative Interview Study. JMIR formative research, 2026
  3. Towards regulatory acceptance of 3D in vitro mucosal models in non-clinical vaccine development and market authorization. NAM journal, 2026
  4. Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America. Infectious diseases and therapy, 2026
  5. A signal-enhanced competitive ELISA based on peptide screened by solid-liquid phase panning hybrid for sensitive detection of respiratory syncytial virus glycoprotein. Analytica chimica acta, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RSV Vaccines in context

Spain compared

  • Health spending per person: 3,107 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.29 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 21.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the RSV Vaccines market in Spain?
Placeholder estimate: about $88.5 Mn in 2025, rising to about $228.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RSV Vaccines market in Spain growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RSV Vaccines market report cover?
The report splits the market by product (Older Adult Vaccines, Maternal Vaccines, Infant Monoclonal Antibodies), age (Infants, Older Adults, Pregnant Women) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RSV Vaccines market?
Key players include GSK PLC, Pfizer Inc., Moderna, Sanofi and AstraZeneca.
What is driving the RSV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Who regulates RSV Vaccines in Spain?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices. Source: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
How is healthcare paid for in Spain?
The National Health System (SNS), run by the regions, gives universal public care. Source: Spanish Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on RSV Vaccines are running in Spain?
4 studies are recruiting, active or about to start in Spain, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
How much research is published on RSV Vaccines?
PubMed lists 397 papers on RSV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about RSV Vaccines in Spain? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Antimicrobial Resistance: Why Faster Testing MattersDrug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the… Needleless Connectors: Small Device, Big Infection ImpactNeedleless connectors protect staff from needle injuries, but if not cleaned they can let germs into the…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Spain

See all
Same topic, other categories

Related on vaccines and respiratory

See the topic